x
CME-Tagline

The Complete Response: Addressing Antidepressant Selection for Patients with Major Depressive Disorder

CMEO Webcast

Premiere Date: Wednesday, September 29, 2021

This activity offers CE credit for:

  1. ABIM (MOC)
  2. Family Physicians (AAFP)
  3. Medicine (accme)
  4. Nursing (ANCC)
  5. Pharmacy (acpe)
  6. PA (aapa)
  7. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, September 29, 2022

Faculty


Michael E. Thase, MD Michael E. Thase, MD (Moderator)
Professor of Psychiatry
Department of Psychiatry
Perelman School of Medicine at the University of Pennsylvania
Corporal Michael J. Crescenz Veterans Affairs Medical Center
Philadelphia, PA

Karen Hyden, PhD, APN-BC, MSN/Ed, ACHPN Karen Hyden, PhD, APN-BC, MSN/Ed, ACHPN 
Area Vice President of Palliative Care, Amedisys, Inc.
Nashville, TN

W. Clay Jackson, MD, DIpTh W. Clay Jackson, MD, DIpTh 
Clinical Assistant Professor
Family Medicine and Psychiatry
University of Tennessee College of Medicine
Memphis, TN

Statement of Need

Major depressive disorder (MDD) is a profoundly debilitating, lifelong disorder. Many patients do not achieve remission with initial first-line antidepressant therapy, which is typically comprised of selective serotonin reuptake inhibitors (SSRIs) or selective norepinephrine reuptake inhibitors (SNRIs). Subsequently, patients endure a high burden of treatment failure, though it is often unrecognized. Measurement-based care (MBC) is a proven strategy for monitoring treatment effectiveness and signaling clinicians when alternate strategies are warranted, yet MBC is not routinely implemented into practice.

This CME Outfitters virtual symposium will provide family medicine clinicians with real-world strategies to incorporate MBC into routine practice to rapidly detect suboptimal treatment outcomes. In addition, faculty experts will guide family medicine clinicians through developing safe and effective alternate antidepressant therapy with unique MOAs when patients experience treatment failures with initial SSRIs/SNRIs.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Incorporate MBC into primary care settings to identify suboptimal treatment responses with initial antidepressant therapy for MDD that can impede remission and functional recovery.
  • Evaluate the impact of antidepressants with unique mechanisms of action (MOAs) on safety, efficacy, and tolerability relative to traditional antidepressants.
  • Apply best practices for switching to antidepressants with a different MOA when initial response to SSRI/SNRI treatment results in residual symptoms, inadequate response, or intolerable side effects.

Financial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Lundbeck.

Target Audience

Family medicine/primary care physicians, nurse practitioners, PAs, nurses, and pharmacists

Credit Information

AAFP Credit (Family Physicians):
The AAFP has reviewed The Complete Response: Addressing Antidepressant Failure in Patients with Major Depressive Disorder and deemed it acceptable for up to 1.50 Online Only, Live AAFP Prescribed credit. Term of Approval is from 09/29/2021 to 09/29/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Thase reports that he receives grants from Acadia Pharmaceuticals Inc.; Allergan; Assurex Health, Inc.; Axsome Therapeutics, Inc.; Biohaven Pharmaceuticals; Intra-Cellular Therapies, Inc.; Johnson & Johnson; Otsuka America Pharmaceutical, Inc.; Patient-Centered Outcomes Research Institute (PCORI); and Takeda Pharmaceuticals U.S.A, Inc. He is a consultant for Acadia Pharmaceuticals Inc.; Akili Inc.; Alkermes; Allergan; Axsome Therapeutics, Inc; Biohaven Pharmaceuticals; Bocemtium Consulting, S.L.; Boehringer Ingelheim International; CatalYm GmbH; Clexio Biosciences; Gerson Lehrman Group, Inc.; H. Lundbeck, A/S; Jazz Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer, Inc.; Sage Therapeutics, Inc.; Seelos Therapeutics, Inc.; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceuticals U.S.A, Inc. He receives royalties from the American Psychiatric Foundation; Guilford Publications; Herald House; Kluwer-Wolters; and W.W. Norton & Company, Inc.

Dr. Hyden has no disclosures to report.

Dr. Jackson reports he is a consultant for AbbVie Inc.; Alkermes; Otsuka America Pharmaceutical, Inc.; and Sunovion Pharmaceuticals Inc.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

MM-117-092921-20